Héctor Guadalajara

Dr. Héctor Guadalajara

General Surgery, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JPJulián Panés
Julián Panés
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
GAGert Van Assche
Gert Van Assche
JCJean Frederic Colombel
Jean Frederic Colombel
WRWalter Reinisch
Walter Reinisch
Héctor GuadalajaraHéctor Guadalajara
Héctor Guadalajara

1 July 2012 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
MHM D Herreros
M D Herreros
MGMariano García-Arranz
Mariano García-Arranz
Héctor GuadalajaraHéctor Guadalajara
Héctor Guadalajara
PDP. De-La-Quintana
P. De-La-Quintana
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
Autologous adipose-derived stem cells may represent a novel approach for the management of complex fistula-in-ano. After successful phase I and II clinical trials, a phase III trial was performed to investigate the safety and efficacy. In this multicenter, randomized, single-blind, add-on clinical trial, 200 adult patients from 19 centers were randomly assigned to receive 20 million stem cells (group A, 64 patients), 20 million adipose-derived stem cells plus fibrin glue (group B, 60 patients), or fibrin glue (group C, 59 patients) after closure of the internal opening. Fistula healing was defined as reepithelization of the external opening and absence of collection >2 cm by MRI. If the fistula had not healed at 12 weeks, a second dose (40 million stem cells in groups A and B) was administered. Patients were evaluated at 24 to 26 weeks (primary end point) and at 1 year (long-term follow-up). All results are according to the "blinded evaluator" assessment. After 24 to 26 weeks, the healing rate was 39.1%, 43.3%, 37.3% in groups A, B, and C (p = 0.79). At 1 year, the healing rates were 57.1%, 52.4%, and 37.3 % (p = 0.13). On analysis of the subpopulation treated at the technique's pioneer center, healing rates were 54.55%, 83.33%, and 18.18%, at 24 to 26 weeks (p < 0.001). No SAEs were reported. In treatment of complex fistula-in-ano, a dose of 20 or 60 million adipose-derived stem cells alone or in combination with fibrin glue was considered a safe treatment, achieving healing rates of approximately 40% at 6 months and of more than 50% at 1-year follow-up. It was equivalent to fibrin glue alone. No statistically significant differences were found when the 3 groups where compared. www.clinicaltrials.gov, identifier NCT00475410; Sponsor, Cellerix SA.

9 November 2011 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
Héctor GuadalajaraHéctor Guadalajara
Héctor Guadalajara
DHDolores Herreros
Dolores Herreros
PDPaloma De-La-Quintana
Paloma De-La-Quintana
JTJacobo Trebol
Jacobo Trebol
MGMariano García-Arranz
Mariano García-Arranz
Damián García-OlmoDamián García-Olmo
Damián García-Olmo

13 July 2016 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
MGMariano García-Arranz
Mariano García-Arranz
MHMaria Dolores Herreros
Maria Dolores Herreros
CGCarolina González-Gómez
Carolina González-Gómez
PQPaloma de la Quintana
Paloma de la Quintana
Héctor GuadalajaraHéctor Guadalajara
Héctor Guadalajara
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
The aim of this clinical trial was to determine the safety and feasibility of expanded allogeneic adipose-derived stem cells to treat Crohn’s-related rectovaginal fistula (CRRVF). We designed a phase I–II clinical trial (https://ClinicalTrials.gov, NCT00999115) to treat 10 patients with CRRVF. Patients receiving biological therapy during follow-up were excluded. Curettage was performed, and a vaginal or rectal flap was added if the surgeon considered it necessary. The therapeutic protocol included intralesional injection of 20 million stem cells in the vaginal walls (submucosal area) and fistula tract. Healing was evaluated 12 weeks later. If the fistula had not healed, a second dose of 40 million stem cells was administered. Patient follow-up was 52 weeks from last cell injection. Healing was defined as re-epithelialization of both vaginal and rectal sides and absence of vaginal drainage. Cytokines and immunological blood tests were monitored. Serious adverse events or rejection issues were not observed. Five patients were excluded because biologic drugs were required to treat a Crohn's disease flare-up during follow-up. Cytokine profiles and immunotoxicity assays showed no statistically significant alterations. Sixty percent of the nonexcluded patients achieved a complete healing. Expanded allogeneic adipose-derived stem-cell injection is a safe and feasible therapy for treating CRRVF, and the healing success rate seems promising (60%). The results of this trial encourage further exploration into this therapy.Significance: This may be the first publication in which allogeneic stem cells to treat rectovaginal fistula in Crohn’s disease seem to be a feasible and safe treatment. Additional studies are necessary to confirm the efficacy profile of the allogeneic stem cells strategy in a controlled design.

25 April 2016 in Nature Medicine
Verified
Journal Article
Closed access
PCPaloma Cejas
Paloma Cejas
LLLewyn Li
Lewyn Li
NONicholas K O'Neill
Nicholas K O'Neill
MDMelissa Duarte
Melissa Duarte
PRPrakash Rao
Prakash Rao
HLHenry W Long
Henry W Long

7 March 2010 in Case Reports in Medicine
Verified
Journal Article
Open access
PDF file
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
DHD. Herreros
D. Herreros
PDP. De-La-Quintana
P. De-La-Quintana
Héctor GuadalajaraHéctor Guadalajara
Héctor Guadalajara
JTJ. Trébol
J. Trébol
MGMariano García-Arranz
Mariano García-Arranz
Therapeutic options for recto-vaginal fistula in the setting of Crohn's disease are limited and many data are available in the literature. The manuscript describes the history of a patient who has been the pioneer of our Clinical Trials in treating this disease in fistulizing Crohn's disease environment. We believe it is the first time that a patient with this disease has been treated by adipose-derived stem cells in allogeneic form. The conclusion of our study with Mary is that the use of mesenchymal stem cells derived from adipose tissue is secure, either in autologous or allogeneic form. Furthermore, we have proved that if we use multi-dose and multiple applications on a patient, it does not produce any adverse effect, which confirms us the safety of using these cells in patients at least in the fistulizing Crohn's disease environment.